Zimmer Biomet (NYSE:ZBH) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research report released on Saturday morning.

Several other equities research analysts have also recently weighed in on the company. UBS Group reduced their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Johnson Rice set a $112.00 price target on Zimmer Biomet in a report on Wednesday. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $101.00 price target on shares of Zimmer Biomet in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $109.42.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.05 during mid-day trading on Friday, hitting $88.46. The company had a trading volume of 2,628,235 shares, compared to its average volume of 1,937,232. The firm has a market cap of $17.53 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet has a 12 month low of $85.33 and a 12 month high of $114.72. The stock’s fifty day moving average price is $100.15 and its two-hundred day moving average price is $97.48.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Key Financial Inc grew its holdings in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares in the last quarter. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter worth approximately $35,000. Root Financial Partners LLC acquired a new stake in Zimmer Biomet during the third quarter valued at approximately $31,000. Finally, Cary Street Partners Investment Advisory LLC boosted its holdings in Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.